IdentifySensors plans to launch graphene-based biosensors in 2026

U.S-based biotech company IdentifySensors, developer of graphene-based biosensors, has announced plans to commercialize its disease testing technology and seek new funding in 2026.

On its website, the Company states that its Check4™ platform enables rapid, lab-free detection of cancers, viruses, and bacteria – no technicians or liquid reagents required. This sensitive, low-cost, electronic biosensor system aims to deliver multiplex molecular testing to the masses, with early cancer screening at its core.

U.S-based biotech company IdentifySensors, developer of graphene-based biosensors, has announced plans to commercialize its disease testing technology and seek new funding in 2026.On its website, the Company states that its Check4™ platform enables rapid, lab-free detection of cancers, viruses, and bacteria – no technicians or liquid reagents required. This sensitive, low-cost, electronic biosensor system aims to deliver multiplex molecular testing to the masses, with early cancer screening at its core.

Read More Graphene-Info – Graphene industry portal